From GlobeNewswire: 2024-03-27 16:01:00

Mereo BioPharma Group plc announced the completion of enrollment expected by the end of Q1 for Phase 2/3 Orbit Study and in the first half of 2024 for Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta. Discussions for partnering alvelestat for Phase 3 are progressing with a partner expected by the end of 2024. The company had $57.4 million in cash as of December 31, 2023 to fund operations into 2026. CEO Dr. Denise Scots-Knight highlighted key milestones achieved in 2023, setting the stage for potential transformation in 2024. Both Phase 3 studies of setrusumab in OI are on track, along with pre-launch activities progressing well. Regulatory guidance for alvelestat in AATD-LD has been received, with partnering discussions ongoing for Phase 3 studies. Mereo remains well positioned for multiple inflection points in the year ahead.



Read more at GlobeNewswire:: Mereo BioPharma Reports Full Year 2023 Financial Results